HBA1C REDUCTION, GLYCAEMIC CONTROL AND DIASTOLIC BLOOD PRESSURE IMPROVEMENT FOLLOWING CDC DM PACKAGE INTERVENTION IN 24 T2DM PATIENTS AT NAVI MUMBAI–NEW PANVEL: A RETROSPECTIVE OBSERVATIONAL STUDY

Background: New Panvel's DM Package cohort is strongly male-predominant (70.8%) with a high proportion of pure DM diagnoses (87.5%), representing a focused diabetic population without significant hypertension confounders. This provides a clean signal for evaluating the protocol's direct glycaemic impact. Objective: To evaluate the effect of the Madhavbaug CDC Panchakarma-based multimodal protocol on glycaemic, anthropometric, cardiometabolic, and medication parameters exclusively in DM Package patients (n=24) at the Navi Mumbai (New Panvel) Central RIC clinic. Methods: Retrospective observational study. 24 T2DM patients enrolled in the DM Package at Navi Mumbai (New Panvel) Central RIC. Only DM Package care plans (CDC-SP Base/1/2/3, CDC-KP Base/1/2/3, DM-HTN 1/2/3) included. Paired Student's t-test (two-tailed) for within-group pre–post comparisons (p<0.05 significant). Descriptive statistics as mean ± SD. Results: HbA1c declined from 8.96±1.74% to 7.70±1.12% (Δ −1.26%, −14.1%, p<0.001, n=19). RBS reduced from 227.50±77.09 to 184.00±69.70 mg/dL (Δ −43.50 mg/dL, −19.1%, p=0.002, n=22). Abdominal girth fell by −1.09 cm (−1.2%, p=0.004, n=22). DBP reduced by −5.18 mmHg (−6.7%, p=0.007, n=22). Heart rate trend: −1.32 bpm (p=0.358). Conclusion: New Panvel's DM Package confirms robust glycaemic improvement — HbA1c −14.1% (p<0.001) and RBS −19.1% (p=0.002) — alongside significant DBP reduction (−5.18 mmHg, p=0.007) and abdominal girth improvement (p=0.004) in 24 predominantly male T2DM patients. The protocol demonstrates reliable glycaemic and cardiometabolic benefit in this focused diabetic cohort.